MIMETAS

We’re excited to be at #AACR2025 next week! Stop by Booth 2741 to explore how our 3D human cancer models are accelerating oncology drug discovery. Join our poster sessions to learn about our latest cancer innovations, including: ✔️ A scalable human liver-on-a-chip model for fibrosis and gene delivery ✔️ On-chip platforms modeling glioblastoma-vasculature interactions ✔️ Patient-derived systems targeting the HCC tumor microenvironment ✔️ Insights into CAR-T migration and cytotoxicity in a co-culture setting 👇 Swipe through the schedule and session highlights. https://lnkd.in/eiM-KUxx #TumorMicroenvironment #ImmunoOncology #LifeSciences #3DCellCulture

On April 10–11, 2025, the GRIPonMASH Consortium gathered for its 2nd annual meeting in the vibrant city of Utrecht, The Netherlands. It was a pleasure to reconnect in person and witness the impressive progress shared by all work package leaders! The collaborative spirit, shared commitment, and remarkable milestones achieved highlight the strength of our consortium as we work together to advance the prevention and care of Metabolic dysfunction-Associated SteatoHepatitis (MASH). A truly energising and inspiring two days! Innovative Health Initiative (IHI) Amsterdam UMC Biocellvia CNR-IFC, National Research Council Institute of Clinical Physiology European Atherosclerosis Society Echosens Elevate European Liver Patients' Association - ELPA EXIT071 Faculdade de Medicina da Universidade de Lisboa Všeobecná fakultní nemocnice v Praze Harokopio University of Athens IHU ICAN Julius Clinical Mercodia Metadeq Diagnostics Maastricht University MEDICAL EDUCATION RESEARCH AND INNOVATION CENTER Leiden University Medical Center MIMETAS Nordic Bioscience Novo Nordisk Servicio Andaluz De Salud UZA Università Cattolica del Sacro Cuore Université libre de Bruxelles UMC Utrecht Universität des Saarlandes Universiteit Leiden (Leiden University) Roche

The FDA has just announced a plan to phase out animal testing requirements for monoclonal antibodies and other therapies — marking a paradigm shift in how we evaluate drug safety.   Instead, the agency is actively promoting the use of modern, human-relevant methods known as "New Approach Methodologies (NAMs)," including: 🔹 AI-based toxicity modeling 🔹 Human cell-based assays 🔹 Microphysiological systems (MPS) — such as organoids and organ-on-a-chip platforms   This move recognizes a reality we’ve long seen at MIMETAS: animal models often fail to predict human response, especially for complex therapies like CAR-T, monoclonal antibodies, and cell/gene therapies. The FDA announcement reinforces what we discussed in last week’s toxicology webinar: the need for human-relevant models in drug development. As modalities evolve, so should our testing frameworks – and this FDA move signals real momentum. 🔗 Read the full FDA announcement: https://lnkd.in/ehX6dX94 🎥 Watch our latest toxicology webinar: https://lnkd.in/dAmmV8_8 📜 Read our publication: https://lnkd.in/eVCbHMw8 #HumanRelevant #DrugDevelopment #OrganOnAChip #AnimalFreeTesting #FDA

If you're working in preclinical research and seeking more predictive in vitro models for assessing drug safety, this one’s for you. Our latest webinar "Opportunities in Toxicity Testing of New Drug Modalities with 3D in vitro Models" is now available to watch anytime! This session explores how advanced 3D human in vitro models can help overcome the limitations of traditional nonclinical safety testing—especially as new drug modalities bring complex, less predictable toxicities. Hear from MIMETAS experts Henriette Lanz, PhD and Dorota Kurek, PhD as they dive into: - Applications of organ-on-a-chip for toxicity testing in peripheral neuropathy, vascular, intestinal, and immune-mediated liver toxicities - How 3D human in vitro models improve human relevance in early drug safety assessments - The evolving role of microphysiological systems in predictive toxicology. 🎥 Watch on demand now: https://lnkd.in/dAmmV8_8 #PreclinicalResearch #Toxicology #3DCellCulture #InVitroModels #MicrophysiologicalSystems

While CAR-T therapies have shown success in hematologic cancers, their effectiveness in solid tumors remains limited by poor T-cell infiltration, antigen heterogeneity, and an immunosuppressive tumor microenvironment (TME). Our CAR-T assay platform addresses this gap by providing a physiologically relevant, scalable microfluidic system that allows for in-depth evaluation of CAR-T behavior in a TME-integrated context. Key Features: 🔹 Vessel-tumor co-culture with perfusable endothelium 🔹T cell extravasation and infiltration modeling 🔹Live imaging of fluorescently labeled CAR-T cells 🔹Customizable TME with primary tumors or cell lines 🔹High-throughput compatible for screening and optimization Download our poster to learn how this assay can support preclinical development of CAR-T therapies for solid tumors: https://lnkd.in/ee4Cb96x #CART #CellTherapy #ImmunoOncology #TumorMicroenvironment #CancerResearch

🎓 Congratulations to Dr. Flavio Bonanini on the successful defense of his PhD! His research focused on developing advanced liver microphysiological systems (MPS) — miniaturized, vascularized liver models designed to mimic real human biology. Conducted at MIMETAS, Flavio’s work highlights scalable, functional liver models with real-world impact — from improving drug screening to reducing development costs for diseases like diabetes and liver fibrosis. We’re proud to have supported Flavio in this exciting step forward for human health. Congrats, Dr. Bonanini! 🥳 Learn more about his liver work in this webinar he presents: https://lnkd.in/eqdEFYaP #PhDDefense #LiverOnAChip #MPS #DrugDevelopment #OrgansOnChips

🎓 Big congratulations to Haley Ehlers on successfully defending her PhD at Universiteit Leiden! 🎉 Her thesis, “Development of a Healthy and Diseased Artery-on-a-Chip”, is the result of the research she conducted at MIMETAS — advancing organ-on-a-chip models for vascular disease and drug development. We’re incredibly proud to have been part of her PhD journey. Well done, Dr. Ehlers!📘 Read her thesis here: https://lnkd.in/eXfDQ3tY #PhDDefense #OrganOnAChip #WomenInSTEM #CardiovascularResearch

Only 4 days left to register for our webinar! ⏳   Join us on Tuesday, April 8, to learn how human 3D in vitro models are being used to improve drug safety assessment and identify modality-mediated toxicities at an early stage.   Our expert speakers, Henriette Lanz, PhD (VP Biology at MIMETAS) and Dorota Kurek, PhD (Senior Scientist at MIMETAS), will discuss: 🔹 The role of 3D human in vitro models in detecting peripheral neuropathy, vascular, intestinal, and immune-mediated hepatotoxicity 🔹 How 3D human in vitro models can help predict human safety risks by uncovering mechanisms underlying clinical adverse events 🔹 Future opportunities for microphysiological systems in toxicity testing   🔗 Sign up now to secure your spot! https://lnkd.in/dAmmV8_8 #Webinar #DrugSafety #Toxicology #3DCellCulture #PreclinicalResearch

🔬 NAMs Are No Longer “Next”—They’re Now. A new industry perspective published in Toxicological Sciences underscores a major shift in regulatory science: the legitimization and strategic integration of New Approach Methodologies (NAMs)—including microphysiological systems (MPS)—into nonclinical safety assessment. With the FDA Modernization Act 2.0/3.0, there’s growing momentum to legitimize NAMs as part of hybrid safety packages. This is a critical step toward human-relevant, data-driven drug development. At MIMETAS, we’re proud to contribute to this shift with 3D human tissue models that help bridge the gap between the lab and the clinic. Read the article: https://lnkd.in/eBeR6wWC 💬 What’s the biggest challenge—or enabler—you see for making NAMs a regulatory standard? Let’s discuss 👇 #NAMs #OrganOnChip #MPS #FDAModernizationAct #RegulatoryScience #DrugDevelopment

Learn What’s Possible with 3D Human Tissue Models: From disease modeling and toxicity screening to barrier function studies and more — see how organ-on-a-chip technology is transforming research. Our whitepapers and application notes highlight real-world use cases, delivering insights that help move science forward. What you’ll find inside: ✔️ Peer-reviewed, scientifically validated data ✔️ Ready-to-use protocols for immediate implementation ✔️ Applications across drug discovery, toxicology, and disease biology ✔️ Results from collaborations with leading pharma, biotech, and academic teams Whether you're new to microphysiological systems or optimizing an advanced workflow, these resources are packed with practical, high-impact knowledge to accelerate your work. 📘 Browse our full collection of whitepapers and application notes: https://lnkd.in/eG8rhuyR #OrganOnAChip #3DCellCulture #TissueModels #LifeSciences